Demystifying drug reaction with eosinophilia and systemic symptoms (DRESS): a review of the literature and guidelines for management.
Antiviral agents
Cyclosporine
DRESS
Drug hypersensitivity syndrome
Eosinophilia
Immunoglobulins
Plasmapheresis
Steroids
Targeted therapy
Journal
Archives of dermatological research
ISSN: 1432-069X
Titre abrégé: Arch Dermatol Res
Pays: Germany
ID NLM: 8000462
Informations de publication
Date de publication:
26 Sep 2024
26 Sep 2024
Historique:
received:
02
01
2024
accepted:
14
09
2024
revised:
04
09
2024
medline:
26
9
2024
pubmed:
26
9
2024
entrez:
26
9
2024
Statut:
epublish
Résumé
Drug reaction with eosinophilia and systemic symptoms (DRESS) is a severe, adverse drug reaction that is notoriously complex in both its presentation and treatment. Although early diagnosis and cessation of the causative agent are universally accepted as the initial interventions for DRESS, the subsequent management lacks a standardized approach. Historically, systemic steroids have been used as first-line treatment, but there is debate about the optimal dosing and route of administration, and evidence persists on the long-term complications associated with steroid use. Novel treatment approaches with targeted therapy, cyclosporine, intravenous immunoglobulin, and plasmapheresis have been gaining interest as alternative mono- and adjuvant therapies, but their use has yet to be supported by clinical trials. This narrative review provides a summary of the current knowledge of DRESS, with a focus on clinical management. The various mono- and adjuvant therapy options are discussed, with literature-supported suggestions for their optimal use in clinical practice. The risks for relapses, viral reactivation, and long-term complications are also considered. The PubMed and Medline databases were searched for articles on DRESS, published between January 1, 2008, and May 1, 2023. 334 articles met the inclusion criteria. Based on the literature, a DRESS management tool with step-by-step guidance is provided. Further suggestions for management are woven throughout this review, giving clinicians a toolbelt of resources with which to approach diagnosis, treatment, and follow-up.
Identifiants
pubmed: 39325061
doi: 10.1007/s00403-024-03389-z
pii: 10.1007/s00403-024-03389-z
doi:
Substances chimiques
Immunoglobulins, Intravenous
0
Cyclosporine
83HN0GTJ6D
Immunosuppressive Agents
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
644Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Fleming P, Marik PE (2011) The DRESS syndrome: the great clinical mimicker. Pharmacotherapy 31(3):45–49. https://doi.org/10.1592/phco.31.3.332
doi: 10.1592/phco.31.3.332
Uhara H, Saiki M, Kawachi S, Ashida A, Oguchi S, Okuyama R (2013) Clinical course of drug-induced hypersensitivity syndrome treated without systemic corticosteroids. J Eur Acad Dermatol Venereol 27(6):722–726. https://doi.org/10.1111/j.1468-3083.2012.04547.x
doi: 10.1111/j.1468-3083.2012.04547.x
pubmed: 22540194
Hashizume H, Ishikawa Y, Ajima S (2022) Is steroid pulse therapy a suitable treatment for drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms? A systematic review of case reports in patients treated with corticosteroids in Japan. J Dermatol 49(2):303–307. https://doi.org/10.1111/1346-8138.16230
doi: 10.1111/1346-8138.16230
pubmed: 34755354
Husain Z, Reddy BY, Schwartz RA (2013) DRESS syndrome: Part I. J Am Acad Dermatol 68(5):709.e1-709.e9. https://doi.org/10.1016/j.jaad.2013.01.032
doi: 10.1016/j.jaad.2013.01.032
pubmed: 23602183
Kardaun SH, Sekula P, Valeyrie-Allanore L, Liss Y, Chu CY, Creamer D, Sidoroff A, Naldi L, Mockenhaupt M, Roujeau JC, RegiSCAR study group (2013) Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study. Br J Dermatol 169(5):1071–1080. https://doi.org/10.1111/bjd.12501
doi: 10.1111/bjd.12501
pubmed: 23855313
Stirton H, Shear NH, Dodiuk-Gad RP (2022) Drug reaction with eosinophilia and systemic symptoms (DReSS)/Drug-induced hypersensitivity syndrome (DiHS)-Readdressing the DReSS. Biomedicines 10(5):999. https://doi.org/10.3390/biomedicines10050999
doi: 10.3390/biomedicines10050999
pubmed: 35625735
pmcid: 9138571
Gottlieb M, Figlewicz MR, Rabah W, Buddan D, Long B (2022) Drug reaction with eosinophilia and systemic symptoms: an emergency medicine focused review. Am J Emerg Med 56:1–6. https://doi.org/10.1016/j.ajem.2022.03.024
doi: 10.1016/j.ajem.2022.03.024
pubmed: 35338896
Shiohara T, Mizukawa Y (2019) Drug-induced hypersensitivity syndrome (DiHS)/drug reaction with eosinophilia and systemic symptoms (DRESS): an update in 2019. Allergol Int 68(3):301–308. https://doi.org/10.1016/j.alit.2019.03.006
doi: 10.1016/j.alit.2019.03.006
pubmed: 31000444
Isaacs M, Cardones AR, Rahnama-Moghadam S (2018) DRESS syndrome: clinical myths and pearls. Cutis 102(5):322–326
pubmed: 30566546
Radovanovic M, Jevtic D, Calvin AD, Petrovic M, Paulson M, Rueda Prada L, Sprecher L, Savic I, Dumic I (2022) “Heart in DRESS”: cardiac manifestations, treatment and outcome of patients with drug reaction with eosinophilia and systemic symptoms syndrome: a systematic review. J Clin Med 11(3):704–706. https://doi.org/10.3390/jcm11030704
doi: 10.3390/jcm11030704
pubmed: 35160164
pmcid: 8836915
Di Palma-Grisi JC, Vijayagopal K, Muslimani MA (2019) Case reports of DRESS syndrome and symptoms consistent with DRESS syndrome following treatment with recently marketed monoclonal antibodies. Autoimmune Dis. https://doi.org/10.1155/2019/7595706
doi: 10.1155/2019/7595706
pubmed: 31308976
pmcid: 6594346
Griffin DWJ, Martin GE, McLean C, Cheng AC, Giles ML (2020) A case of drug reaction with eosinophilia and systemic symptoms (DRESS) without a typical precipitant. Med J Aust 212(7):300-301.e1. https://doi.org/10.5694/mja2.50519
doi: 10.5694/mja2.50519
pubmed: 32092152
Lospinoso K, Nichols CS, Malachowski SJ, Mochel MC, Nutan F (2021) A case of severe cutaneous adverse reaction following administration of the Janssen Ad26.COV2.S COVID-19 vaccine. JAAD Case Rep 13:134–137. https://doi.org/10.1016/j.jdcr.2021.05.010
doi: 10.1016/j.jdcr.2021.05.010
pubmed: 34056055
pmcid: 8149168
Schunkert EM, Divito SJ (2021) Updates and insights in the diagnosis and management of DRESS syndrome. Curr Dermatol Rep 10(4):192–204. https://doi.org/10.1007/s13671-021-00348-z
doi: 10.1007/s13671-021-00348-z
pubmed: 34777921
pmcid: 8577395
Nguyen K, Ahmed MS (2018) Drug rash with eosinophilia and systemic symptoms syndrome presenting after the initiation of staphylococcus hominis infectious endocarditis treatment: a case report and updated review of management considerations. Cureus 10(12):e3679. https://doi.org/10.7759/cureus.3679
doi: 10.7759/cureus.3679
pubmed: 30761231
pmcid: 6367119
Martínez-Cabriales SA, Rodríguez-Bolaños F, Shear NH (2019) Drug reaction with eosinophilia and systemic symptoms (DReSS): how far have we come? Am J Clin Dermatol 20(2):217–236. https://doi.org/10.1007/s40257-018-00416-4
doi: 10.1007/s40257-018-00416-4
pubmed: 30652265
Cabañas R, Ramírez E, Sendagorta E, Alamar R, Barranco R, Blanca-López N, Doña I, Fernández J, Garcia-Nunez I, García-Samaniego J, Lopez-Rico R, Marín-Serrano E, Mérida C, Moya M, Ortega-Rodríguez NR, Rivas Becerra B, Rojas-Perez-Ezquerra P, Sánchez-González MJ, Vega-Cabrera C, Vila-Albelda C, Bellón T (2020) Spanish guidelines for diagnosis, management, treatment, and prevention of DRESS syndrome. J Investig Allergol Clin Immunol 30(4):229–253. https://doi.org/10.18176/jiaci.0480
doi: 10.18176/jiaci.0480
pubmed: 31932268
Cacoub P, Musette P, Descamps V, Meyer O, Speirs C, Finzi L, Roujeau JC (2011) The DRESS syndrome: a literature review. Am J Med 124(7):588–597. https://doi.org/10.1016/j.amjmed.2011.01.017
doi: 10.1016/j.amjmed.2011.01.017
pubmed: 21592453
Hama N, Abe R, Gibson A, Phillips EJ (2022) Drug-induced hypersensitivity syndrome (DIHS)/drug reaction with eosinophilia and systemic symptoms (DRESS): clinical features and pathogenesis. J Allergy Clin Immunol Pract 10(5):1155-1167.e5. https://doi.org/10.1016/j.jaip.2022.02.004
doi: 10.1016/j.jaip.2022.02.004
pubmed: 35176506
pmcid: 9201940
Wu WH, Chu CY (2022) Annular drug eruptions. Clin Dermatol 40(5):450–465. https://doi.org/10.1016/j.clindermatol.2021.12.008
doi: 10.1016/j.clindermatol.2021.12.008
pubmed: 34979270
Kwon H, Yoon J (2023) Comparison of cyclosporine and systemic corticosteroid for treating drug reaction with eosinophilia and systemic symptoms syndrome: a retrospective 20-year single-centre study in South Korea. Australas J Dermatol. https://doi.org/10.1111/ajd.13982
doi: 10.1111/ajd.13982
pubmed: 36695042
Shiohara T, Kano Y, Hirahara K, Aoyama Y (2017) Prediction and management of drug reaction with eosinophilia and systemic symptoms (DRESS). Expert Opin Drug Metab Toxicol 13(7):701–704. https://doi.org/10.1080/17425255.2017.1297422
doi: 10.1080/17425255.2017.1297422
pubmed: 28633581
Ali SB, Schweikert S, Brusch A (2021) Drug reaction with eosinophilia and systemic symptoms syndrome secondary to acetazolamide associated with markedly elevated procalcitonin. BMJ Case Rep 14(1):e236966. https://doi.org/10.1136/bcr-2020-236966
doi: 10.1136/bcr-2020-236966
pubmed: 33462002
pmcid: 7813420
Descamps V, Ben Saïd B, Sassolas B, Truchetet F, Avenel-Audran M, Girardin P, Guinnepain MT, Mathelier-Fusade P, Assier H, Milpied B, Modiano P, Lebrun-Vignes B, Barbaud A, groupe Toxidermies de la Société française de dermatologie (2010) Management of drug reaction with eosinophilia and systemic symptoms (DRESS). Ann Dermatol Venereol 137(11):703–708. https://doi.org/10.1016/j.annder.2010.04.024
doi: 10.1016/j.annder.2010.04.024
pubmed: 21074653
Taweesedt PT, Nordstrom CW, Stoeckel J, Dumic I (2019) Pulmonary manifestations of drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: a systematic review. BioMed Res Int. https://doi.org/10.1155/2019/7863815
doi: 10.1155/2019/7863815
pubmed: 31662996
pmcid: 6778864
Eshki M, Allanore L, Musette P, Milpied B, Grange A, Guillaume JC, Chosidow O, Guillot I, Paradis V, Joly P, Crickx B, Ranger-Rogez S, Descamps V (2009) Twelve-year analysis of severe cases of drug reaction with eosinophilia and systemic symptoms. A cause of unpredictable multiorgan failure. Arch Dermatol 145(1):67–72. https://doi.org/10.1001/archderm.145.1.67
doi: 10.1001/archderm.145.1.67
pubmed: 19153346
Bourgeois GP, Cafardi JA, Groysman V, Pamboukian SV, Kirklin JK, Andea AA, Hughey LC (2011) Fulminant myocarditis as a late sequela of DRESS: two cases. J Am Acad Dermatol 65(4):889–890. https://doi.org/10.1016/j.jaad.2010.10.036
doi: 10.1016/j.jaad.2010.10.036
pubmed: 21920256
pmcid: 3511821
Thongsri T, Chularojanamontri L, Pichler WJ (2017) Cardiac involvement in DRESS syndrome. Asian Pac J Allergy Immunol 35(1):3–10. https://doi.org/10.12932/AP0847
doi: 10.12932/AP0847
pubmed: 27996289
Cho Y-T, Yang C-W, Chu C-Y (2017) Drug reaction with eosinophilia and systemic symptoms (DRESS): an interplay among drugs, viruses, and immune system. Int J Mol Sci 18(6):1243. https://doi.org/10.3390/ijms18061243
doi: 10.3390/ijms18061243
pubmed: 28598363
pmcid: 5486066
Shiohara T, Kano Y (2012) Drug-induced hypersensitivity syndrome: Recent advances in drug allergy. Expert Rev Dermatol 7(6):539–547. https://doi.org/10.1586/edm.12.45
doi: 10.1586/edm.12.45
Ramirez GA, Ripa M, Burastero S, Benanti G, Bagnasco D, Nannipieri S, Monardo R, Ponta G, Asperti C, Cilona MB, Castagna A, Dagna L, Yacoub MR (2023) Drug reaction with eosinophilia and systemic symptoms (DRESS): focus on the pathophysiological and diagnostic role of viruses. Microorganisms 11(2):346. Available at https://www.mdpi.com/2076-2607/11/2/346 .
Miyagawa F, Asada H (2021) Current perspective regarding the immunopathogenesis of drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms (DIHS/DRESS). Int J Mol Sci 22(4):2147. https://doi.org/10.3390/ijms22042147
doi: 10.3390/ijms22042147
pubmed: 33670052
pmcid: 7927043
Wung CH, Wang CW, Lai KC, Chen CB, Chen WT, Hung SI, Chung WH (2023) Current understanding of genetic associations with delayed hypersensitivity reactions induced by antibiotics and anti-osteoporotic drugs. Front Pharmacol. https://doi.org/10.3389/fphar.2023.1183491
doi: 10.3389/fphar.2023.1183491
pubmed: 37180708
pmcid: 10169607
Moling O, Tappeiner L, Piccin A, Pagani E, Rossi P, Rimenti G, Vedovelli C, Mian P (2012) Treatment of DIHS/DRESS syndrome with combined N-acetylcysteine, prednisone and valganciclovir—a hypothesis. Med Sci Monit 18(7):CS57–CS62. https://doi.org/10.12659/msm.883198
doi: 10.12659/msm.883198
pubmed: 22739739
pmcid: 3560780
Su T, Xiong W, Xu Y, Lu Y (2021) Allopurinol-induced drug reaction with eosinophilia and systemic symptoms syndrome associated with reactivation of Epstein-Barr virus leading to secondary hemophagocytic lymphohistiocytosis in an HLA-B ∗5801-negative patient. Indian J Dermatol Venereol Leprol 87:545–548. https://doi.org/10.25259/IJDVL_925_20
doi: 10.25259/IJDVL_925_20
pubmed: 34219434
Kridin K, Brüggen MC, Walsh S, Bensaid B, Ranki A, Oppel E, Meyersburg D, Chua SL, Seeli C, Sandberg H, French LE, Vorobyev A, Ingen-Housz-Oro S (2022) Management and treatment outcome of DRESS patients in Europe: An international multicentre retrospective study of 141 cases. J Eur Acad Dermatol Venereol 37(4):753–762. https://doi.org/10.1111/jdv.18808
doi: 10.1111/jdv.18808
pubmed: 36479739
Cardones AR (2020) Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome. Clin Dermatol 38(6):702–711. https://doi.org/10.1016/j.clindermatol.2020.06.008
doi: 10.1016/j.clindermatol.2020.06.008
pubmed: 33341203
Bommersbach TJ, Lapid MI, Leung JG, Cunningham JL, Rummans TA, Kung S (2016) Management of psychotropic drug–induced DRESS syndrome: a systematic review. Mayo Clin Proc 91(6):787–801. https://doi.org/10.1016/j.mayocp.2016.03.006
doi: 10.1016/j.mayocp.2016.03.006
pubmed: 27126302
Criado PR, Criado RF, Avancini JM, Santi CG (2012) Drug reaction with eosinophilia and systemic symptoms (DRESS)/drug-induced hypersensitivity syndrome (DIHS): a review of current concepts. An Bras Dermatol 87(3):435–449. https://doi.org/10.1590/s0365-05962012000300013
doi: 10.1590/s0365-05962012000300013
pubmed: 22714760
De A, Rajagopalan M, Sarda A, Das S, Biswas P (2018) Drug reaction with eosinophilia and systemic symptoms: An update and review of recent literature. Indian J Dermatol 63(1):30–40. https://doi.org/10.4103/ijd.IJD_582_17
doi: 10.4103/ijd.IJD_582_17
pubmed: 29527023
pmcid: 5838752
Funck-Brentano E, Duong TA, Bouvresse S, Bagot M, Wolkenstein P, Roujeau JC, Chosidow O, Valeyrie-Allanore L (2015) Therapeutic management of DRESS: a retrospective study of 38 cases. J Am Acad Dermatol 72(2):246–252. https://doi.org/10.1016/j.jaad.2014.10.032
doi: 10.1016/j.jaad.2014.10.032
pubmed: 25592341
Brin C, Bernigaud C, Hua C, Duong TA, Gaudin O, Colin A, de Prost N, Wolkenstein P, Chosidow O, Ingen-Housz-Oro S (2021) Impact of systemic to topical steroids switch on the outcome of drug reaction with eosinophilia and systemic symptoms (DRESS): a monocenter retrospective study of 20 cases. Ann Dermatol Venereol 148(3):168–171. https://doi.org/10.1016/j.annder.2021.02.002
doi: 10.1016/j.annder.2021.02.002
pubmed: 33858692
Tohyama M, Hashimoto K, Oda F, Namba C, Sayama K (2020) Influence of corticosteroid therapy on viral reactivation in drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms. J Dermatol 47(5):476–482. https://doi.org/10.1111/1346-8138.15294
doi: 10.1111/1346-8138.15294
pubmed: 32162382
pmcid: 7754408
Husain Z, Reddy BY, Schwartz RA (2013) DRESS syndrome: Part II. Management and therapeutics. J Am Acad Dermatol 68(5):709.e1-709.e9. https://doi.org/10.1016/j.jaad.2013.01.032
doi: 10.1016/j.jaad.2013.01.032
pubmed: 23602183
Hamm RL (2011) Drug-hypersensitivity syndrome: diagnosis and treatment. J Am Coll Clin Wound Spec 3(4):77–81. https://doi.org/10.1016/j.jcws.2012.06.001
doi: 10.1016/j.jcws.2012.06.001
pubmed: 24527369
Lee JH, Park HK, Heo J, Kim TO, Kim GH, Kang DH, Song GA, Cho M, Kim DS, Kim HW, Lee CH (2008) Drug rash with eosinophilia and systemic symptoms (DRESS) syndrome induced by celecoxib and anti-tuberculosis drugs. J Korean Med Sci 23(3):521–525. https://doi.org/10.3346/jkms.2008.23.3.521
doi: 10.3346/jkms.2008.23.3.521
pubmed: 18583892
pmcid: 2526540
Sim DW, Yu J, Koh YI (2022) Efficacy of add-on therapy with intravenous immunoglobulin in steroid hyporesponsive DRESS syndrome. Clin Transl Sci 15(3):782–788. https://doi.org/10.1111/cts.13201
doi: 10.1111/cts.13201
pubmed: 34796665
Brandariz D, Smithson A, Anton-Vazquez V (2017) Drug reaction with eosinophilia and systemic symptoms related to antiretroviral treatment in human immunodeficiency virus patients. Indian J Sex Transm Dis 38(2):163–170. https://doi.org/10.4103/ijstd.IJSTD_70_17
doi: 10.4103/ijstd.IJSTD_70_17
Joly P, Janela B, Tetart F, Rogez S, Picard D, D’Incan M, Descamps V, Collet E, Roujeau JC, Musette P (2011) Poor benefit/risk balance of intravenous immunoglobulins in DRESS. Arch Dermatol 148(4):543–544. https://doi.org/10.1001/archdermatol.2011.1937
doi: 10.1001/archdermatol.2011.1937
Kito Y, Ito T, Tokura Y, Hashizume H (2012) High-dose intravenous immunoglobulin monotherapy for drug-induced hypersensitivity syndrome. Acta Derm Venereol 92(1):100–101. https://doi.org/10.2340/00015555-1168
doi: 10.2340/00015555-1168
pubmed: 21681351
Mizukawa Y, Aoyama Y, Takahashi H, Takahashi R, Shiohara T (2022) Risk of progression to autoimmune disease in severe drug eruption: risk factors and the factor-guided stratification. J Invest Dermatol 142(3):960-968.e9. https://doi.org/10.1016/j.jid.2021.11.008
doi: 10.1016/j.jid.2021.11.008
pubmed: 34808234
Maverakis E, Ji-Xu A, Brüggen MC (2022) Targeting interleukin-5 with benralizumab: a novel treatment for drug rash with eosinophilia and systemic symptoms. Allergy 77(8):2287–2289. https://doi.org/10.1111/all.15283
doi: 10.1111/all.15283
pubmed: 35285038
Chowdhury M, Azari BM, Desai NR, Ahmad T (2020) A novel treatment for a rare cause of cardiogenic shock. JACC Case Rep 2(10):1461–1465. https://doi.org/10.1016/j.jaccas.2020.02.004
doi: 10.1016/j.jaccas.2020.02.004
pubmed: 34316997
pmcid: 8302098
Leman RE, Chen L, Shi X, Rolimpandoei SP, Ling X, Su Y (2017) Drug reaction with eosinophilia and systemic symptoms (DRESS) successfully treated with tumor necrosis factor-α inhibitor. JAAD Case Rep 3(4):332–335. https://doi.org/10.1016/j.jdcr.2017.05.006
doi: 10.1016/j.jdcr.2017.05.006
pubmed: 28752124
pmcid: 5518151
Yordanova K, Pföhler C, Schweitzer LF, Bourg C, Adam L, Vogt T (2022) Etanercept leads to a rapid recovery of a dabrafenib/trametinib-associated toxic epidermal necrolysis-like severe skin reaction. Skin Health Dis 3(1):e185. https://doi.org/10.1002/ski2.185
doi: 10.1002/ski2.185
pubmed: 36751314
pmcid: 9892424
Rubin L, Talmon A, Ribak Y, Kessler A, Martin Y, Haran TK, Shamriz O, Adini I, Tal Y (2023) Novel targeted inhibition of the IL-5 axis for drug reaction with eosinophilia and systemic symptoms syndrome. Front Immunol 14:1134178. https://doi.org/10.3389/fimmu.2023.1134178
doi: 10.3389/fimmu.2023.1134178
pubmed: 37187735
pmcid: 10175640
Thein OS, Sutton B, Thickett DR, Parekh D (2019) Mepolizumab rescue therapy for acute pneumonitis secondary to DRESS. BMJ Case Rep 12(10):e231355. https://doi.org/10.1136/bcr-2019-231355
doi: 10.1136/bcr-2019-231355
pubmed: 31604720
pmcid: 6803131
Truong K, Kelly S, Bayly A, Smith A (2021) Successful mepolizumab treatment for DRESS-induced refractory eosinophilic myocarditis and concurrent thyroiditis. BMJ Case Rep 14(7):e242240. https://doi.org/10.1136/bcr-2021-242240
doi: 10.1136/bcr-2021-242240
pubmed: 34266818
pmcid: 8286746
Mesli F, Dumont M, Soria A, Groh M, Turpin M, Voiriot G, Rafat C, Sallé DS, Gibelin A, Desnos C (2021) Benralizumab: a potential tailored treatment for life-threatening DRESS in the COVID-19 era. J Allergy Clin Immunol Practice 9(9):3529–3531. https://doi.org/10.1016/j.jaip.2021.06.047
doi: 10.1016/j.jaip.2021.06.047
Ange N, Alley S, Fernando SL, Coyle L, Yun J (2018) Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome successfully treated with mepolizumab. J Allergy Clin Immunol 6(3):1059–1060. https://doi.org/10.1016/j.jaip.2017.10.020
doi: 10.1016/j.jaip.2017.10.020
Kowtoniuk R, Pinninti M, Tyler W, Doddamani S (2018) DRESS syndrome-associated acute necrotizing eosinophilic myocarditis with giant cells. BMJ Case Rep. https://doi.org/10.1136/bcr-2018-226461
doi: 10.1136/bcr-2018-226461
pubmed: 30301732
pmcid: 6194447
Kim S, Joo EJ, Kim UJ, Kim JH, Kim B, Lee HJ, Chae SW, Kim HN, Cheong HS (2022) Corticosteroid-induced drug reaction with eosinophilia and systematic symptoms successfully treated with a tumor necrosis factor alpha inhibitor. Asian Pac J Allergy Immunol 40(4):418–421. https://doi.org/10.12932/ap-210819-0628
doi: 10.12932/ap-210819-0628
pubmed: 32170921
Vílchez-Sánchez F, Busto Leis JM, Sendagorta E, Ramírez E, Fiandor A, Bellón T, De Soto Álvarez T, Sánchez Ocando H, Heredia Revuelto R, Cabañas R (2022) Allopurinol-induced DRESS and neosensitization to thalidomide: complex management and diagnosis in a patient with multiple myeloma. J Investig Allergol Clin Immunol 32(5):406–407. https://doi.org/10.18176/jiaci.0776
doi: 10.18176/jiaci.0776
pubmed: 35029153
Kim D, Kobayashi T, Voisin B, Jo JH, Sakamoto K, Jin SP, Kelly M, Pasieka HB, Naff JL, Meyerle JH, Ikpeama ID, Fahle GA, Davis FP, Rosenzweig SD, Alejo JC, Pittaluga S, Kong HH, Freeman AF, Nagao K (2020) Targeted therapy guided by single-cell transcriptomic analysis in drug-induced hypersensitivity syndrome: a case report. Nat Med 26(2):236–243. https://doi.org/10.1038/s41591-019-0733-7
doi: 10.1038/s41591-019-0733-7
pubmed: 31959990
pmcid: 7105105
Maximova N, Maestro A, Zanon D, Marcuzzi A (2020) Rapid recovery of postnivolumab vemurafenib-induced drug rash with eosinophilia and systemic symptoms (DRESS) syndrome after tocilizumab and infliximab administration. J ImmunoTherapy Cancer 8(1):e000388. https://doi.org/10.1136/jitc-2019-000388
doi: 10.1136/jitc-2019-000388
Park H, Choi GS, Lee EM (2021) ’Successful treatment of imatinib-induced DRESS syndrome using reslizumab without cessation of imatinib: a case report’. Case Rep Oncol 14(3):1548–1554. https://doi.org/10.1159/000519471
doi: 10.1159/000519471
pubmed: 34899250
pmcid: 8613629
Adil M, Amin S, Mohtashim M (2018) N-acetylcysteine in dermatology. Indian J Dermatol Venereol Leprol 84(6):652. https://doi.org/10.4103/ijdvl.IJDVL_33_18
doi: 10.4103/ijdvl.IJDVL_33_18
pubmed: 30246706
Ton A, Kassab L, Patel A, Dawson N (2020) Severe acute hepatitis in drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome resolved following cyclosporine. J Allergy Clin Immunol Pract 8(1):398–400. https://doi.org/10.1016/j.jaip.2019.06.020
doi: 10.1016/j.jaip.2019.06.020
pubmed: 31271919
Brizendine CE, Naik PJ (2013) Drug rash with eosinophilia and systemic symptoms syndrome associated with use of phenytoin, divalproex sodium, and phenobarbital. Am J Health Syst Pharm 70(6):507–510. https://doi.org/10.2146/ajhp120408
doi: 10.2146/ajhp120408
pubmed: 23456403
Fridey JL, Kaplan AA (2022) Therapeutic apheresis (plasma exchange or cytapheresis): indications and technology. UptoDate. https://www.uptodate.com/contents/therapeutic-apheresis-plasma-exchange-or-cytapheresis-indications-and-technology .
Miyazaki M, Tanaka M, Ueda A, Yoshimoto T, Kato M, Nakamuta M, Kotoh K, Takayanagi R (2011) Acute liver failure caused by drug-induced hypersensitivity syndrome associated with hyperferritinemia. World J Gastroenterol 17(44):4928–4931. https://doi.org/10.3748/wjg.v17.i44.4928
doi: 10.3748/wjg.v17.i44.4928
pubmed: 22171136
pmcid: 3235638
Shen Q, Wang Q, Zang H, Yu L, Cong X, Chen X, Chen L (2023) DRESS/DiHS syndrome induced by propylthiouracil: a case report. BMC Endocr Disorders 23(1):273. https://doi.org/10.1186/s12902-023-01273-x
doi: 10.1186/s12902-023-01273-x
Nie Y, Wang H, Dong X, Pan S, Zhang T, Ran J, Zhang Y, Fan J, Zhang L, Wang J (2022) Case report: Drug rash with eosinophilia and systemic symptoms syndrome in a patient with anti–interferon-γ autoantibody–associated immunodeficiency. Front Immunol 13:969912. https://doi.org/10.3389/fimmu.2022.969912
doi: 10.3389/fimmu.2022.969912
pubmed: 36072590
pmcid: 9441898
Shaughnessy KK, Bouchard SM, Mohr MR, Herre JM, Salkey KS (2010) Minocycline-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome with persistent myocarditis. J Am Acad Dermatol 62(2):315–318. https://doi.org/10.1016/j.jaad.2009.05.046
doi: 10.1016/j.jaad.2009.05.046
pubmed: 19665822
Duong TA, Valeyrie-Allanore L, Wolkenstein P, Chosidow O (2017) Severe cutaneous adverse reactions to drugs. The Lancet 390(10106):1996–2011. https://doi.org/10.1016/S0140-6736(16)30378-6
doi: 10.1016/S0140-6736(16)30378-6
Mustafa SS, Ostrov D, Yerly D (2018) Severe cutaneous adverse drug reactions: Presentation, risk factors, and management. Curr Allergy Asthma Rep 18(4):26. https://doi.org/10.1007/s11882-018-0778-6
doi: 10.1007/s11882-018-0778-6
pubmed: 29574562
Asano Y, Kagawa H, Kano Y, Shiohara T (2009) Cytomegalovirus disease during severe drug eruptions: report of 2 cases and retrospective study of 18 patients with drug-induced hypersensitivity syndrome. Arch Dermatol 145(9):1030–1036. Available at https://jamanetwork.com/ .
Ben Said B, Gerfaud-Valentin M, Seve P (2018) Fatal DRESS syndrome under tocilizumab treatment for seronegative polyarthritis. J Allergy Clin Immunol Pract 6(3):1048–1049. https://doi.org/10.1016/j.jaip.2017.08.041
doi: 10.1016/j.jaip.2017.08.041
pubmed: 29126664
Takamiyagi S et al (2022) Severe graft-versus-host disease-like enterocolitis accompanied with cytomegalovirus-reactivation in drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms. J Dermatol 49(8):796–799. https://doi.org/10.1111/1346-8138.16415
doi: 10.1111/1346-8138.16415
pubmed: 35502510
Laban E, Hainaut-Wierzbicka E, Pourreau F, Yacoub M, Sztermer E, Guillet G, Touchard G, Bridoux F (2010) Cyclophosphamide therapy for corticoresistant drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome in a patient with severe kidney and eye involvement and Epstein-Barr virus reactivation. Am J Kidney Dis 55(3):11–14. https://doi.org/10.1053/j.ajkd.2009.10.054
doi: 10.1053/j.ajkd.2009.10.054
Hagiwara H, Fukushima A, Iwano H, Anzai T (2018) Refractory cardiac myocarditis associated with drug rash with eosinophilia and systemic symptoms syndrome due to anti-bipolar disorder drugs: a case report. Eur Heart J Case Rep 2(4):yty100. https://doi.org/10.1093/ehjcr/yty100
doi: 10.1093/ehjcr/yty100
pubmed: 31020177
pmcid: 6426116
Bourgeois GP, Cafardi JA, Groysman V, Hughey LC (2012) A review of DRESS-associated myocarditis. J Am Acad Dermatol 66(6):e229–e236. https://doi.org/10.1016/j.jaad.2010.11.057
doi: 10.1016/j.jaad.2010.11.057
pubmed: 21658796
Ingen-Housz-Oro S, Staumont-Sallé D, Palladini A, Ferries L, Chiaverini C, Valois A, Tieulié N, Bernigaud C, Milpied B (2021) Immunosuppressants as steroid-sparing agents for chronic DRESS: four cases. Eur J Dermatol 31(4):574–576. https://doi.org/10.1684/ejd.2021.4102
doi: 10.1684/ejd.2021.4102
Chiang PH, Ng CY, Kuo TT, Hui RCY, Chen CB, Lu CW, Chung WH (2021) Case of vitiligo universalis as a sequela of drug-induced hypersensitivity syndrome. J Dermatol 48(1):92–95. https://doi.org/10.1111/1346-8138.15562
doi: 10.1111/1346-8138.15562
pubmed: 33180345
Picard D, Vellar M, Janela B, Roussel A, Joly P, Musette P (2015) Recurrence of drug-induced reactions in DRESS patients. J Eur Acad Dermatol Venereol 29(4):801–804. https://doi.org/10.1111/jdv.12419
doi: 10.1111/jdv.12419
pubmed: 24628777
Sharma AN, Shwe S, Ravi V, Miller M, Mesinkovska NA, Rojek NW, Worswick S (2021) Characterizing DRESS syndrome recurrence: a systematic review. Arch Dermatol Res 314(8):721–728. https://doi.org/10.1007/s00403-021-02274-3
doi: 10.1007/s00403-021-02274-3
pubmed: 34505944
Jörg L, Helbling A, Yerly D, Pichler WJ (2020) Drug-related relapses in drug reaction with eosinophilia and systemic symptoms (DRESS). Clin Transl Allergy 10(1):52. https://doi.org/10.1186/s13601-020-00359-2
doi: 10.1186/s13601-020-00359-2
pubmed: 33292540
pmcid: 7682085
Tan SC, Chan GYL (2016) Relapsing drug-induced hypersensitivity syndrome. Curr Opin Allergy Clin Immunol 16(4):333–338. https://doi.org/10.1097/ACI.0000000000000288
doi: 10.1097/ACI.0000000000000288
pubmed: 27362321
Chen YC, Chang CY, Cho YT, Chiu HC, Chu CY (2013) Long-term sequelae of drug reaction with eosinophilia and systemic symptoms: a retrospective cohort study from Taiwan. J Am Acad Dermatol 68(3):459–465. https://doi.org/10.1016/j.jaad.2012.08.009
doi: 10.1016/j.jaad.2012.08.009
pubmed: 22959230
Ushigome Y, Kano Y, Ishida T, Hirahara K, Shiohara T (2013) Short-and long-term outcomes of 34 patients with drug-induced hypersensitivity syndrome in a single institution. J Am Acad Dermatol 68(5):721–728. https://doi.org/10.1016/j.jaad.2012.10.017
doi: 10.1016/j.jaad.2012.10.017
pubmed: 23182063
Ang CC, Wang YS, Yoosuff ELM, Tay YK (2010) Retrospective analysis of drug-induced hypersensitivity syndrome: A study of 27 patients. J Am Acad Dermatol 63(2):219–227. https://doi.org/10.1016/j.jaad.2009.08.050
doi: 10.1016/j.jaad.2009.08.050
pubmed: 20605253
Della-Torre E, Yacoub MR, Pignatti P, Della-Torre F, Sabbadini MG, Colombo G, Tresoldi M (2013) Optimal management of DRESS syndrome in course of infectious endocarditis. Ann Allergy Asthma Immunol 110(4):303–305. https://doi.org/10.1016/j.anai.2013.01.006
doi: 10.1016/j.anai.2013.01.006
pubmed: 23535099